T Cell Ig and Mucin Domain–Containing Protein 3 Is Recruited to the Immune Synapse, Disrupts Stable Synapse Formation, and Associates with Receptor Phosphatases
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
CD8+ CTLs are adept at killing virally infected cells and cancer cells and releasing cytokines (e.g., IFN-γ) to aid this response. However, during cancer and chronic viral infections, such as with HIV, this CTL response is progressively impaired due to a process called T cell exhaustion. Previous work has shown that the glycoprotein T cell Ig and mucin domain–containing protein 3 (Tim-3) plays a functional role in establishing T cell exhaustion. Tim-3 is highly upregulated on virus and tumor Ag-specific CD8+ T cells, and antagonizing Tim-3 helps restore function of CD8+ T cells. However, very little is known of how Tim-3 signals in CTLs. In this study, we assessed the role of Tim-3 at the immunological synapse as well as its interaction with proximal TCR signaling molecules in primary human CD8+ T cells. Tim-3 was found within CD8+ T cell lipid rafts at the immunological synapse. Blocking Tim-3 resulted in a significantly greater number of stable synapses being formed between Tim-3hiCD8+ T cells and target cells, suggesting that Tim-3 plays a functional role in synapse formation. Further, we confirmed that Tim-3 interacts with Lck, but not the phospho-active form of Lck. Finally, Tim-3 colocalizes with receptor phosphatases CD45 and CD148, an interaction that is enhanced in the presence of the Tim-3 ligand, galectin-9. Thus, Tim-3 interacts with multiple signaling molecules at the immunological synapse, and characterizing these interactions could aid in the development of therapeutics to restore Tim-3–mediated immune dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Another inhibitory signaling mechanism discussed is the colocalization of TIM‐3 with CD45 and CD148 at the immunological synapse, where T cell function was suppressed [313].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [313]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“However, these mechanisms also limit T cell responses to cancer Ags and chronic infection (1, 2).”
BackgroundMolecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114 · cited 1×
“Formation of an immunological synapse requires a T cell in conjugate with a target cell to provide a TCR stimulus and surface ligands/receptors on both cells to coordinate multiple costimulatory/inhibitory and immune accessory molecules (35, 36).”
BackgroundBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · cited 1×
“In addition, antagonizing these receptors with Abs or soluble fusion proteins results in partial rescue of effector function (6).”
BackgroundThe Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057 · cited 2×
“Tim-3 is carbohydrate dependent (17), and as such, galectin-9’s”
BackgroundWherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R., & Ahmed, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4911-4927.2003 · Cited by 1,610
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528 · cited 1×
“However, these mechanisms also limit T cell responses to cancer Ags and chronic infection (1, 2).”
BackgroundMonney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E. A., Coyle, A. J., Sobel, R. A., et al. (2002) · Nature · doi:10.1038/415536a · Cited by 1,472
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · cited 1×
“Similarly, PD-1 has also been found at the immunological synapse and negatively effects synapse stability, as defined by concentrated and centered CD3 at the T cell synapse (38).”
BackgroundCooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Jin, H.-T., Anderson, A. C., Tan, W. G., West, E. E., Ha, S.-J., Araki, K., Freeman, G. J., Kuchroo, V. K., & Ahmed, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009731107 · Cited by 858
Jones, R. B., Ndhlovu, L. C., Barbour, J. D., Sheth, P. M., Jha, A. R., Long, B. R., Wong, J. C., Satkunarajah, M., Schweneker, M., Chapman, J. M., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081398 · Cited by 753 · cited 2×
“Soluble Tim-3 (sTim-3) was produced and purified as previously described (4) and biotinylated using the EZ-Link Sulfo-NHS-LC-Biotinylation Kit (Thermo Scientific, Rockford, IL).”
BackgroundMethodSelf-citation
Cited by
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
“Another work showed that TIM3 interacted with multiple proximal TCR signaling molecules in the immune synapse, with TIM3 blockade enhancing stable synapse formation between TIM3 CD8 T cells and target cells.(90) TIM3 contains five conserved tyrosine residues in its cytoplasmic domain, among which Y265 (Y256 in mouse)…”
BackgroundTIM3 comes of age as an inhibitory receptor
Wolf, Y., Anderson, A. C., & Kuchroo, V. K. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0224-6 · Cited by 959
Tim‐3 and its role in regulating anti‐tumor immunity
Das, M., Zhu, C., & Kuchroo, V. K. (2017) · Immunological Reviews · doi:10.1111/imr.12520 · Cited by 856
Tim-3 finds its place in the cancer immunotherapy landscape
Acharya, N., Sabatos-Peyton, C., & Anderson, A. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000911 · Cited by 394
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Kurachi, M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00744-5 · Cited by 314
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation
Joller, N., Anderson, A. C., & Kuchroo, V. K. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.010 · Cited by 249
TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
Du, W., Yang, M., Turner, A., Xu, C., Ferris, R., Huang, J., Kane, L., & Lu, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030645 · Cited by 242
“TIM-3 has also been sh wn to inh bit TCR proximal signali g [47,48].”
BackgroundInfluentialNagahara, K., Arikawa, T., Oomizu, S., Kontani, K., Nobumoto, A., Tateno, H., Watanabe, K., Niki, T., Katoh, S., Miyake, M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.7660 · Cited by 207
Modulation of regulatory T cell function and stability by co-inhibitory receptors
Lucca, L. E., & Dominguez-Villar, M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0296-3 · Cited by 189
Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
Ferris, R. L., Lu, B., & Kane, L. P. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400557 · Cited by 173
“ported that Tim-3 can associate with the transmembrane phosphatases CD45 and CD148, which the investigators proposed might promote dephosphorylation of downstream mediators of T cell activation (44).”
BackgroundAvery, L., Filderman, J., Szymczak-Workman, A. L., & Kane, L. P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712107115 · Cited by 169
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy
Gaikwad, S. R., Agrawal, M. Y., Kaushik, I., Ramachandran, S., & Srivastava, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.014 · Cited by 172
The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy
Kandel, S., Adhikary, P., Li, G., & Cheng, K. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.011 · Cited by 165
Galectin-9 suppresses B cell receptor signaling and is regulated by I-branching of N-glycans
Giovannone, N., Liang, J., Antonopoulos, A., Geddes Sweeney, J., King, S. L., Pochebit, S. M., Bhattacharyya, N., Lee, G. S., Dell, A., Widlund, H. R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05770-9 · Cited by 143
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
Sauer, N. J., Janicka, N., Szlasa, W., Skinderowicz, B., Kołodzińska, K., Dwernicka, W., Oślizło, M., Kulbacka, J., Novickij, V., & Karłowicz-Bodalska, K. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03516-1 · Cited by 157
“This protein is recruited to the immune synapse upon CD8 + T cell activation, which has a significant role in regulating the immune response [38].”
Backgroundİmani, S., Farghadani, R., Roozitalab, G., Maghsoudloo, M., Emadi, M., Moradi, A., Abedi, B., & Kaboli, P. J. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03394-8 · Cited by 131
Sabatos-Peyton, C. A., Nevin, J. T., Brock, A., Venable, J. D., Tan, D. J., Kassam, N., Xu, F., Taraszka, J. A., Wesemann, L. D., Pertel, T., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1385690 · Cited by 124
“been shown to promote recruitment of Tim-3 to the immunological synapse, where Tim-3 can co-localize with phosphatases (CD45 and CD148) that antagonize proximal TCR signaling.(19)”
BackgroundGalectin-9 binds IgM-BCR to regulate B cell signaling
Cao, A., Alluqmani, N., Buhari, F. H. M., Wasim, L., Smith, L. K., Quaile, A. T., Shannon, M., Hakim, Z., Furmli, H., Owen, D. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05771-8 · Cited by 105
Banerjee, H., Nieves-Rosado, H. M., Kulkarni, A., Murter, B., McGrath, K. V., Chandran, U. R., Chang, A., Szymczak-Workman, A. L., Vujanovic, L. N., Delgoffe, G. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109699 · Cited by 112
Galectin-9: From cell biology to complex disease dynamics
John, S., & Mishra, R. (2016) · Journal of Biosciences · doi:10.1007/s12038-016-9616-y · Cited by 111
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 99
“Both CEACAM1-L and TIM-3 can recruit SHP-1/SHP-2 phosphatases, respectively, in an ITIM-dependent manner and Lck, CD45, CD148 at the immune synapse to suppress T cell receptor (TCR) signalling (Izzi et al., 1999; Clayton et al., 2014).”
BackgroundTIM-3 pathway dysregulation and targeting in cancer
Zeidan, A. M., Komrokji, R. S., & Brunner, A. M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1865814 · Cited by 97
Clayton, K., Douglas-Vail, M. B., Rahman, A. K. M. N.-U., Medcalf, K. E., Xie, I. Y., Chew, G. M., Tandon, R., Lanteri, M. C., Norris, P. J., Deeks, S. G., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00006-15 · Cited by 102
“Indeed, galectin-9 is able to bind to multiple immune accessory molecules (37, 54, 55) and induce apoptosis in a Tim-3-independent manner (54).”
BackgroundSelf-citationBanerjee, H., & Kane, L. (2018) · F1000Research · doi:10.12688/f1000research.13446.1 · Cited by 98
Tomkowicz, B., Walsh, E., Cotty, A., Verona, R., Sabins, N., Kaplan, F., Santulli-Marotto, S., Chin, C.-N., Mooney, J., Lingham, R. B., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140694 · Cited by 83
“Further evidence supporting the notion that TIM-3 plays an important role in membrane proximal signaling events within the immunological synapse was shown in primary human TIM-3 T cells [39, 40].”
BackgroundTIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives
Yan, Z., Wang, C., Wu, J., Wang, J., & Ma, T. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00267-6 · Cited by 88
“T cell activity is reportedly inhibited when TIM-3 co-localizes at the immunological synapse with CD45 and CD148 [59, 60].”
Regulation of T cell responses by the receptor molecule Tim-3
Gorman, J. V., & Colgan, J. D. (2014) · Immunologic Research · doi:10.1007/s12026-014-8524-1 · Cited by 94
“More recent work employing human primary CD8 T cells showed that Tim-3 associates with the immune synapse formed between CD8 T cells and target cells and that Tim-3 colocalizes with phosphatases that can suppress T cell receptor (TCR) signaling [19].”
BackgroundTandon, R., Chew, G. M., Byron, M. M., Borrow, P., Niki, T., Hirashima, M., Barbour, J. D., Norris, P. J., Lanteri, M. C., Martin, J. N., et al. (2014) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2014.0004 · Cited by 82
“We and others have observed that Tim3 + CD8 + T cells are increased in progressive HIV infection, and engagement presumably through a Gal-9 interaction leads to CD8 + T cell dysfunction.(33,60,62,63) During chronic HIV infection, Gal-9-expressing Treg cells are presumed to selectively suppress the proliferation of non…”
BackgroundSelf-citationAstrocyte galectin-9 potentiates microglial TNF secretion
Steelman, A. J., & Li, J. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0144-0 · Cited by 76
New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors
de Morais, A. L. G., Cerdá, S. S., & Miguel, M. J. D. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01218-y · Cited by 78
Immune Checkpoint Receptors Signaling in T Cells
Baldanzi, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073529 · Cited by 80
“Ti -3 is actively recr ited t the IS, where it associates with ther transmembrane pro eins, including the CD45 and CD148 phosphatases, which may perturb IS stability [72,73].”
BackgroundCoinhibitory receptors and CD8 T cell exhaustion in chronic infections
Kuchroo, V. K., Anderson, A. C., & Petrovas, C. (2014) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000088 · Cited by 84
Tim-3 mediates T cell trogocytosis to limit antitumor immunity
Pagliano, O., Morrison, R. M., Chauvin, J.-M., Banerjee, H., Davar, D., Ding, Q., Tanegashima, T., Gao, W., Chakka, S. R., Deblasio, R. N., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152864 · Cited by 78
“Our findings show that Tim-3, which is recruited to the immunological synapse upon T cell activation (39, 40), plays a critical role in driving pMHC and membrane-associated protein transfer from Tim-3+ APCs to PS+ activated T cells both in vitro and in melanoma-bearing mice, regulating T cell trogocytosis and fratrici…”
BackgroundDual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy
Bangayan, N. J., Wang, L., Sojo, G. B., Noguchi, M., Cheng, D., Ta, L. H., Gunn, D., Mao, Z., Liu, S., Yin, Q., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2312374120 · Cited by 76
“TIM - 3 is thought to function by either destabilizing the immunological synapse through the recruitment of phosphatases or recruiting FYN and CSK to the membrane to inactivate Lck (75, 76).”
BackgroundCurrent Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Cai, X., Zhan, H., Ye, Y., Yang, J., Zhang, M., Li, J., & Zhuang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.785153 · Cited by 66
Carnosine regulation of intracellular pH homeostasis promotes lysosome-dependent tumor immunoevasion
Yan, R., Zhang, P., Shen, S., Zeng, Y., Wang, T., Chen, Z., Ma, W., Feng, J., Suo, C., Zhang, T., et al. (2024) · Nature Immunology · doi:10.1038/s41590-023-01719-3 · Cited by 69
“…our data revealed that the endogenous galectin-9 blot we detected is consistent with the overexpressed galectin-9 (uniport ID #O00182-2), which has been reported to suppress CD8 + T cells in vivo 47 , thus confirming that the blot of galectin-9 showed in this study is correct (Extended Data Fig.”
Phosphatidylserine binding directly regulates TIM-3 function
Smith, C. M., Li, A., Krishnamurthy, N., & Lemmon, M. A. (2021) · Biochemical Journal · doi:10.1042/bcj20210425 · Cited by 61
Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance
Vautrot, V., Bentayeb, H., Causse, S., Garrido, C., & Gobbo, J. (2021) · Cancers · doi:10.3390/cancers13184537 · Cited by 58
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55
Kataoka, S., Manandhar, P., Lee, J., Workman, C. J., Banerjee, H., Szymczak-Workman, A. L., Kvorjak, M., Lohmueller, J. J., & Kane, L. (2021) · Science Signaling · doi:10.1126/scisignal.aba0717 · Cited by 54
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
Chongsaritsinsuk, J., Steigmeyer, A. D., Mahoney, K. E., Rosenfeld, M. A., Lucas, T. M., Smith, C. M., Li, A., Ince, D., Kearns, F. L., Battison, A. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41756-y · Cited by 52
“Forinstance, the TIM-3 ligand Gal-9 is a bivalent lectin that binds glycoproteins decorated with the LacNAc (Gal-GlcNAc) structure and has been shown to crosslink receptors at the cell surface 71,72 .”
Association of TIM-3 expression with glucose metabolism in Jurkat T cells
Lee, M. J., Yun, S. J., Lee, B., Jeong, E., Yoon, G., Kim, K. H., & Park, S. (2020) · BMC Immunology · doi:10.1186/s12865-020-00377-6 · Cited by 51
Galectin-9 promotes natural killer cells activity via interaction with CD44
Rahmati, A., Bigam, S., & Elahi, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1131379 · Cited by 49
Schwartz, J. A., Clayton, K., Mujib, S., Zhang, H., Rahman, A. K. M. N.-U., Liu, J., Yue, F. Y., Benko, E., Kovacs, C. M., & Ostrowski, M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601298 · Cited by 47
Self-citationIdentification and characterization of M6903, an antagonistic anti–TIM-3 monoclonal antibody
Zhang, D., Jiang, F., Zaynagetdinov, R., Huang, H., Sood, V. D., Wang, H., Zhao, X., Jenkins, M. H., Ji, Q., Wang, Y., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1744921 · Cited by 49
Köhler, N., Ruess, D. A., Kesselring, R., & Zeiser, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.634435 · Cited by 48
Gravelle, P., Do, C., Franchet, C., Müller, S., Obéric, L., Ysebaert, L., Larocca, L. M., Hohaus, S., Calmels, M., Frénois, F.-X., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1224044 · Cited by 49
“A recent study reported that TIM-3 expression inhibits TCR signaling and affects the stability of immunological synapses.(20) Although Clayton et al.”
BackgroundMethodInfluentialWang, J., Wang, Y., Jiang, X., Xu, M., Wang, M., Wang, R., Zheng, B., Chen, M., Qi, K., & Long, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216758 · Cited by 44
Unraveling the Role of Immune Checkpoints in Leishmaniasis
Silva, R. D. F. E., & von Stebut, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.620144 · Cited by 49
Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies
Stachyra, K., Dudzisz‐Śledź, M., Bylina, E., Szumera‐Ciećkiewicz, A., Spalek, M. J., Bartnik, E., Rutkowski, P. L., & Czarnecka, A. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126305 · Cited by 43
Influencing immunity: role of extracellular vesicles in tumor immune checkpoint dynamics
Ye, Z., Li, G., & Lei, J. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01340-w · Cited by 42
Homayouni, V., Ganjalıkhani-Hakemi, M., Rezaei, A., Khanahmad, H., Behdani, M., & Kazemi‐Lomedasht, F. (2016) · PubMed Central · doi:10.22038/ijbms.2016.7820 · Cited by 46
The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells
Zhang, J., Wang, L., Guo, H., Kong, S., Li, W., He, Q., Ding, L., & Yang, B. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107458 · Cited by 42
TIM‐3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways
Kikushige, Y. (2021) · Cancer Science · doi:10.1111/cas.15042 · Cited by 39
Yang, R., & Hung, M. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9176-7 · Cited by 37
Chen, H., Moussa, M., & Catálfamo, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01223 · Cited by 38
“In human CD8T cells, TIM3 is localized in lipid rafts and its blockade allows formation of a stable immunological synapse (176).”
BackgroundRiva, A., Palma, E., Devshi, D., Corrigall, D., Adams, H., Heaton, N. D., Menon, K., Preziosi, M., Zamalloa, A., Miquel, R., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.632502 · Cited by 33
Zhai, Y., Celis‐Gutierrez, J., Voisinne, G., Mori, D., Girard, L., Burlet‐Schiltz, O., de Peredo, A. G., Roncagalli, R., & MALISSEN, B. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00575-7 · Cited by 32
Roussot, N., Kaderbhaï, C., & Ghiringhelli, F. (2025) · Cancers · doi:10.3390/cancers17050906 · Cited by 34
“Galectin-9 ligation to TIM-3 can also recruit CD45 and CD148 phosphatases and disrupt the immunological synapse to further inhibit T cell functionality [176].”
Xiang, S., Li, S., & Xu, J. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70345 · Cited by 36
“89,94 When T cells are activated, TIM-3 is drawn to the IS, interacting with BAT3 and the tyrosine kinase Lck 96 (Figure 4).”
InfluentialThe immunological synapse as a pharmacological target
Finetti, F., & Baldari, C. T. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.009 · Cited by 32
Chen, H., Zha, J., Tang, R., & Chen, G. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110418 · Cited by 31
Huang, S., Kang, Y., Liu, T., Xiong, Y., Yang, Z., & Zhang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561968 · Cited by 30
Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics
Naidoo, D. B., & Chuturgoon, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189778 · Cited by 28
“The formation of stable synapses was increased by the Tim-3 blockade [109].”
BackgroundLopresti, L., Tatangelo, V., Baldari, C. T., & Patrussi, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1418527 · Cited by 28
Translational Implication of Galectin-9 in the Pathogenesis and Treatment of Viral Infection
Lai, J., Luo, S., Wang, M., & Ho, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102108 · Cited by 27
“reported that galectin-9 binds to multiple immune accessory molecules, such as the receptor phosphatases CD45 and CD148; moreover, by binding to these two molecules, galectin-9 enhances their interaction with Tim-3 within the CD3 signaling complexes [27].”
BackgroundJu, M.-H., Byun, K.-D., Park, E. H., Lee, J., & Han, S. (2021) · Biomedicines · doi:10.3390/biomedicines9101383 · Cited by 25
Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure
Laderach, D. J., & Compagno, D. (2021) · Cancers · doi:10.3390/cancers13184529 · Cited by 23
Lefebvre, A., Trioën, C., Renaud, S., Laine, W., Hennart, B., Bouchez, C., Leroux, B., Allorge, D., Kluza, J., Werkmeister, E., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12390 · Cited by 22
“According to current knowledge, when TIM3 is free of ligand, BAT3 is retain at its cytoplasmic tail and helps in activating signalling of T cell (Clayton et al., 2014).”
BackgroundLiikanen, I., Basnet, S., Quixabeira, D. C. A., Taipale, K., Hemminki, O., Oksanen, M., Kankainen, M., Juhila, J., Kanerva, A., Joensuu, T. K., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003490 · Cited by 23
A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy
Kuang, Z., Li, L., Zhang, P., Chen, B., Wu, M., Ni, H., Yi, S., Zou, J., & Liu, J. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa022 · Cited by 22
“The complete shutdown of galectin-9/TIM-3 interaction is also critical because galectin-9 has been reported to mediate TIM-3 incorporation into immunological synapses, and co-localize with CD45 phosphatases to dampen TCR signaling [14].”
BackgroundTim-3 pathway dysregulation and targeting in sepsis-induced immunosuppression
Luo, J., Zhang, C., Chen, D., Chang, T., Chen, S., Lin, Z., Yi, C., & Tang, Z. (2024) · European journal of medical research · doi:10.1186/s40001-024-02203-w · Cited by 20
Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy
Li, Y., Kang, Z., & Du, Y. (2026) · Medicine Bulletin · doi:10.1002/mdb2.70018 · Cited by 22
Attias, M., & Piccirillo, C. A. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16313 · Cited by 20
“…immunoreceptor tyrosine-based inhibition motif (ITIM) or immunore-ceptor tyrosine-based switch motif (ITSM) domains, disrupts the immune synapse upon binding to its ligand, Galectin-9, by associating with receptor phosphatases such as CD45 to dampen Lck phosphorylation (Clayton et al., 2014).”
Gorman, J. V., & Colgan, J. D. (2018) · Immunology · doi:10.1111/imm.12890 · Cited by 17
Huang, R., Meng, T., Zhu, R., Zhao, L., Song, D., Yin, H., Huang, Z., Cheng, L., & Zhang, J. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00101 · Cited by 16
Capitani, N., Patrussi, L., & Baldari, C. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011221 · Cited by 16
The Role of TIM-3 in Glioblastoma Progression
Ahmady, F., Sharma, A., Achuthan, A. A., Kannourakis, G., & Luwor, R. B. (2025) · Cells · doi:10.3390/cells14050346 · Cited by 16
“These processes include the phosphorylation of TIM-3, BAT3 disassociation, potential enhanced TIM-3 binding of Fyn [64], phosphatase CD45 and CD148, and less BAT3/LCK association, which all leads to reduced TCR signaling [44,64,65].”
Role of Tim-3 in regulating tumorigenesis, inflammation, and antitumor immunity therapy
Cao, Y., Li, Q., Liu, H., He, X., Huang, F., & Wang, Y. (2021) · Cancer Biomarkers · doi:10.3233/cbm-210114 · Cited by 15
“Also, Tim-3 can be recruited to the immune synapse on CD8 + T-cell activation, which spoils a stable synapse formation, and interacts with receptor phosphatases CD45 and CD148 [51], signifying a different mechanism of Tim-3–mediated immune dysfunction and exhaustion.”
Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy
Peng, Y., Zhan, L., Shi, J., Wang, J., Li, Y., Sun, X., Lv, J., Yang, H., Qiu, Z., Liu, X., et al. (2025) · MedComm · doi:10.1002/mco2.70321 · Cited by 15
The study of immune checkpoint inhibitors in chronic hepatitis B virus infection
Li, S., Li, N., Yang, S., Deng, H., Li, Y., Wang, Y., Jiaqiang, Y., Lv, J., Dong, L., Yu, G., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108842 · Cited by 14
Leveraging T cells for cancer immunotherapy
Bates, A., Fletcher, N. E., Gao, F., Pinho, M. P., & Dong, T. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00007-z · Cited by 13
“following antigen stimulation and inflammatory cytokine signalling [20–29].”
Quilbé, A., Mustapha, R., Duchêne, B., Kumar, A., Werkmeister, E., Leteurtre, E., Moralès, O., Jonckheere, N., SEUNINGEN, I. V., & Delhem, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1267279 · Cited by 12
Zhao, T., Guo, Y. H., & Li, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1336839 · Cited by 11
Involvement of Tim-3 in Maternal-fetal Tolerance: A Review of Current Understanding
Meng, X., Luo, Y., Cui, L., & Wang, S. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.106115 · Cited by 11
“Blocking Tim-3 results in significantly increased stable synapses between CD8 + T cells and target cells[23].”
InfluentialSlaats, J., Dieteren, C. E. J., Wagena, E., Wolf, L., Raaijmakers, T. K., van der Laak, J. A. W. M., Figdor, C. G., Weigelin, B., & Friedl, P. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0741 · Cited by 12
“Lactose protects effector CTLs from inhibitory immune checkpoint signaling by antagonizing the ligand binding function of galectins (28).”
BackgroundTIM3 is a context-dependent coregulator of cytotoxic T cell function
Alamir, H., Wong, C. C. W., Alsubaiti, A., Edmunds, G. L., Alismail, M., Huynh, L., Shi, Y., Lewis, P. A., Grant, T., Alsulaimani, S., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adk4594 · Cited by 10
Human γδ T Cell Function Is Impaired Upon Mevalonate Pathway Inhibition
Suen, T. K., Al, B., Ulas, T., Reusch, N., Bahrar, H., Bekkering, S., Bhat, J., Kabelitz, D., Schultze, J. L., van de Veerdonk, F. L., et al. (2025) · Immunology · doi:10.1111/imm.13931 · Cited by 10
“This suggests that TIM3 signalling, which interferes with the proximal TCR signalling [75, 76], might not be the main driving mechanism of the impaired Vδ2 T cell function as suggested by the RNA-seq and flow cytometry results (Figures 3 and S3).”
Braun, M. W., Abdelhakim, H., Li, M., Hyter, S. D., Pessetto, Z. Y., Koestler, D. C., Pathak, H. B., Dunavin, N., & Godwin, A. K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000706 · Cited by 9
Immunosuppressive immune microenvironment landscapes in VISTA-high gastric cancer
Luo, Y., Peng, H., Yao, Q., Xie, Y., Liu, D., Wang, Y., Peng, Z., Shen, L., Sun, Y., Zhang, X., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-025-03290-0 · Cited by 8
Immune checkpoint TIM-3 in tumor immunotherapy
Ma, S., Zhu, M., Ma, C., & Li, C. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025235 · Cited by 7
“This inhibition is achieved through the suppression of Lck - mediated phosphorylation of the TCR and the production of IFN - γ , TNF - α , and IL - 2 [48,49].”
Teagle, A. R., Castro-Sánchez, P., Brownlie, R. J., Logan, N., Kapoor, S. S., Wright, D., Salmond, R. J., & Zamoyska, R. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007614 · Cited by 7
“TIM-3 has been shown to interact with both Lck(50) and 425 Fyn(39) when it is bound or unbound, respectively, by ligand; since Lck and Fyn are 426 substrates of PTPN22(51,52) there may be direct interaction between TIM-3 and 427 PTPN22-mediated signaling.”
BackgroundWang, S., Wang, Y., Guan, L.-S., Shen, A., Huang, R.-J., Yuan, S., Xiao, Y.-L., Wang, L., Lei, D., Zhao, Y., et al. (2025) · BMC Medical Genomics · doi:10.1186/s12920-024-02082-4 · Cited by 7
“Additionally, HAVCR2 can disrupt immune synapses by binding to receptor phosphatases CD45 and CD148 [72].”
Berclaz, L. M., Altendorf-Hofmann, A., Lindner, L. H., Burkhard‐Meier, A., Gioia, D. D., Dürr, H. R., Klein, A., Albertsmeier, M., Schmidt-Hegemann, N.-S., Klauschen, F., et al. (2023) · Cancers · doi:10.3390/cancers15102735 · Cited by 7
The emerging role of TIM-3 in colorectal cancer: a promising target for immunotherapy
Karami, R., Fathi, M., Jalali, P., Hassannia, H., Zarei, A., Hojjat‐Farsangi, M., & Jadidi‐Niaragh, F. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2442437 · Cited by 7
“One possible explanation for the downregulation of T cells is that Gal-9 helps TIM-3 integrate into immunological synapses and, when it co-localizes with CD45 phosphatases, reduces signaling from T cell receptors (TCRs) [78].”
Regulation of Tim-3 function by binding to phosphatidylserine
Kane, L. (2021) · Biochemical Journal · doi:10.1042/bcj20210652 · Cited by 6
New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine
Zheng, R., Li, Y., Shi, K., Pan, Y., Liu, K., Song, J., & Li, L. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101206 · Cited by 4
“TIM-3 further impairs T-cell function by interacting with CD45/CD148 phosphatases, destabilizing immunological synapse integrity [67].”
Metadata
- Authors
- Clayton, K. L., Haaland, M. S., Douglas-Vail, M. B., Mujib, S., Chew, G. M., Ndhlovu, L. C., & Ostrowski, M. A.
- Affiliations
- University of Toronto (CA)
- University of Hawaiʻi at Mānoa (US)
- St. Michael's Hospital (CA)
- Corresponding author
- Ostrowski, Mario A
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01
- Volume
- 192
- Issue
- 2
- Pages
- 782-791
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC4214929
- OpenAlex
- W2121603793
- Cited by
- 134
- References
- 48
- Citations by year
- 2026: 11 · 2025: 20 · 2024: 14 · 2023: 15 · 2022: 8 · 2021: 19 · 2020: 13 · 2019: 3 · 2018: 8 · 2017: 7 · 2016: 4 · 2015: 4 · 2014: 8
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R56AI083112, P30AI027763)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- TIM-3, immunological synapse, CD8+ T cells, T cell exhaustion, galectin-9, Lck, CD45, CD148, lipid rafts, T cell signaling
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Humans, Membrane Proteins, Phosphoric Monoester Hydrolases, Synapses, Signal Transduction, HIV Infections, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Lymphocyte Specific Protein Tyrosine Kinase p56(lck), Galectins, Receptor-Like Protein Tyrosine Phosphatases, Class 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.